These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
54 related articles for article (PubMed ID: 30034587)
21. Multicentric Glioma: An Ideal Model to Reveal the Mechanism of Glioma. Yan Y; Dai W; Mei Q Front Oncol; 2022; 12():798018. PubMed ID: 35747806 [TBL] [Abstract][Full Text] [Related]
22. Synthesis and Evaluation of a Chitneni SK; Yan H; Zalutsky MR ACS Med Chem Lett; 2018 Jul; 9(7):606-611. PubMed ID: 30034587 [TBL] [Abstract][Full Text] [Related]
23. Synthesis and evaluation of radiolabeled AGI-5198 analogues as candidate radiotracers for imaging mutant IDH1 expression in tumors. Chitneni SK; Reitman ZJ; Spicehandler R; Gooden DM; Yan H; Zalutsky MR Bioorg Med Chem Lett; 2018 Feb; 28(4):694-699. PubMed ID: 29366652 [TBL] [Abstract][Full Text] [Related]
24. Synthesis and biological evaluation of novel PET tracers [ Wang T; Lin Q; Zhang Y; Xu Z; Shi D; Cheng Y; Fu Z; Tan H; Cheng D; Shi H Bioorg Med Chem; 2022 Jan; 53():116525. PubMed ID: 34871844 [TBL] [Abstract][Full Text] [Related]
25. Prediction of Overall Survival Based on Isocitrate Dehydrogenase 1 Mutation and 18F-FDG Uptake on PET/CT in Patients With Cerebral Gliomas. Kim D; Kim S; Kim SH; Chang JH; Yun M Clin Nucl Med; 2018 May; 43(5):311-316. PubMed ID: 29485450 [TBL] [Abstract][Full Text] [Related]
26. Prognostic Value of O-(2-[18F]-Fluoroethyl)-L-Tyrosine-Positron Emission Tomography Imaging for Histopathologic Characteristics and Progression-Free Survival in Patients with Low-Grade Glioma. Bette S; Gempt J; Delbridge C; Kirschke JS; Schlegel J; Foerster S; Huber T; Pyka T; Zimmer C; Meyer B; Ringel F World Neurosurg; 2016 May; 89():230-9. PubMed ID: 26855307 [TBL] [Abstract][Full Text] [Related]
27. AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic Yen K; Travins J; Wang F; David MD; Artin E; Straley K; Padyana A; Gross S; DeLaBarre B; Tobin E; Chen Y; Nagaraja R; Choe S; Jin L; Konteatis Z; Cianchetta G; Saunders JO; Salituro FG; Quivoron C; Opolon P; Bawa O; Saada V; Paci A; Broutin S; Bernard OA; de Botton S; Marteyn BS; Pilichowska M; Xu Y; Fang C; Jiang F; Wei W; Jin S; Silverman L; Liu W; Yang H; Dang L; Dorsch M; Penard-Lacronique V; Biller SA; Su SM Cancer Discov; 2017 May; 7(5):478-493. PubMed ID: 28193778 [TBL] [Abstract][Full Text] [Related]
28. 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity. Sulkowski PL; Corso CD; Robinson ND; Scanlon SE; Purshouse KR; Bai H; Liu Y; Sundaram RK; Hegan DC; Fons NR; Breuer GA; Song Y; Mishra-Gorur K; De Feyter HM; de Graaf RA; Surovtseva YV; Kachman M; Halene S; Günel M; Glazer PM; Bindra RS Sci Transl Med; 2017 Feb; 9(375):. PubMed ID: 28148839 [TBL] [Abstract][Full Text] [Related]
29. Radiolabeled inhibitors as probes for imaging mutant IDH1 expression in gliomas: Synthesis and preliminary evaluation of labeled butyl-phenyl sulfonamide analogs. Chitneni SK; Reitman ZJ; Gooden DM; Yan H; Zalutsky MR Eur J Med Chem; 2016 Aug; 119():218-30. PubMed ID: 27163884 [TBL] [Abstract][Full Text] [Related]
30. Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma. de la Fuente MI; Young RJ; Rubel J; Rosenblum M; Tisnado J; Briggs S; Arevalo-Perez J; Cross JR; Campos C; Straley K; Zhu D; Dong C; Thomas A; Omuro AA; Nolan CP; Pentsova E; Kaley TJ; Oh JH; Noeske R; Maher E; Choi C; Gutin PH; Holodny AI; Yen K; DeAngelis LM; Mellinghoff IK; Thakur SB Neuro Oncol; 2016 Feb; 18(2):283-90. PubMed ID: 26691210 [TBL] [Abstract][Full Text] [Related]
35. Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo. Popovici-Muller J; Saunders JO; Salituro FG; Travins JM; Yan S; Zhao F; Gross S; Dang L; Yen KE; Yang H; Straley KS; Jin S; Kunii K; Fantin VR; Zhang S; Pan Q; Shi D; Biller SA; Su SM ACS Med Chem Lett; 2012 Oct; 3(10):850-5. PubMed ID: 24900389 [TBL] [Abstract][Full Text] [Related]
36. Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1. Davis MI; Gross S; Shen M; Straley KS; Pragani R; Lea WA; Popovici-Muller J; DeLaBarre B; Artin E; Thorne N; Auld DS; Li Z; Dang L; Boxer MB; Simeonov A J Biol Chem; 2014 May; 289(20):13717-25. PubMed ID: 24668804 [TBL] [Abstract][Full Text] [Related]
37. IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Beiko J; Suki D; Hess KR; Fox BD; Cheung V; Cabral M; Shonka N; Gilbert MR; Sawaya R; Prabhu SS; Weinberg J; Lang FF; Aldape KD; Sulman EP; Rao G; McCutcheon IE; Cahill DP Neuro Oncol; 2014 Jan; 16(1):81-91. PubMed ID: 24305719 [TBL] [Abstract][Full Text] [Related]
38. Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas. Jin G; Reitman ZJ; Duncan CG; Spasojevic I; Gooden DM; Rasheed BA; Yang R; Lopez GY; He Y; McLendon RE; Bigner DD; Yan H Cancer Res; 2013 Jan; 73(2):496-501. PubMed ID: 23204232 [TBL] [Abstract][Full Text] [Related]